Kopran Ltd
Pharmaceuticals & Biotechnology | Small Cap
Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio3.20
- Profitability Ratio9.80
- Efficiency Ratio3.00
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio5.44
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
56.51
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
25.82
P/B RATIO
1.98
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
1.58
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
2.08
EV/EBITDA RATIO
12.63
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹206.27 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤22nd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
The company showcases very strong growth across all metrics. High revenue growth, operating profit growth, EPS growth, asset growth, and net income growth indicate robust expansion and market performance. This suggests effective strategies and strong market positioning. The healthcare industry benefits from consistent growth to meet increasing demand.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -2.85 | 15.27 | 11.62 | 2.44 | 8.1 |
| Operating Profit Growth Rate | 6.1 | -40.23 | 42.31 | -1.35 | -15.07 |
| Earnings Per Share (EPS) Growth | -11.1 | -55.37 | 87.08 | -24.41 | -33.29 |
| Asset Growth Rate | 39.18 | 6.38 | 14.31 | 13.59 | 7.58 |
| Net Income Growth Rate | -1.61 | -55.74 | 88.89 | -23.53 | -33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present mixed results. While the dividend per share is reasonable, low adjusted EPS, cash EPS, book value per share, and high capital expenditures suggest areas needing improvement. Enhancing earnings and managing capital expenditures could strengthen financial performance. The healthcare industry requires strong financial management for optimal results.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 12.71 | 5.62 | 10.62 | 8.12 | 5.42 |
| Cash Earnings Per Share (Cash EPS) | 15 | 8.33 | 13.33 | 11.46 | 8.96 |
| Book Value Per Share | 88.75 | 91.46 | 102.29 | 107.92 | 110.42 |
| Dividend Per Share (DPS) | 3.04 | 2.99 | 2.96 | 3.04 | 0 |
| Capital Expenditures (CapEx) | 43 | 61 | 57 | 59 | 66 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits strong profitability. High gross profit margin, ROCE, ROE, ROA, operating margin, and net margin indicate efficient operations and strong returns. This reflects effective management and a competitive market position. The healthcare industry benefits from high profitability to support ongoing operations and growth.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 15.9 | 7.08 | 9.92 | 9.05 | 6.61 |
| Return on Capital Employed (ROCE) | 21 | 8 | 14 | 10 | 7 |
| Return on Equity (ROE) | 14.32 | 6.15 | 10.39 | 7.53 | 4.91 |
| Return on Assets (ROA) | 14.24 | 8 | 9.96 | 8.65 | 6.83 |
| Operating Margin | 18.2 | 9.44 | 12.03 | 11.59 | 9.1 |
| Net Margin | 12.76 | 4.9 | 8.29 | 6.19 | 3.82 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios indicate potential areas of concern. Turnover ratios are low, suggesting inefficient asset utilization. High days sales in inventory and receivable days point to challenges in managing inventory and collecting payments. Enhancing operational efficiency could improve overall performance. The healthcare industry requires efficient asset management for optimal profitability.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.17 | 3.34 | 3.38 | 3.03 | 1.85 |
| Inventory Turnover Ratio | 3.21 | 3.64 | 4.11 | 3.73 | 3.82 |
| Receivables Turnover Ratio | 3.87 | 3.8 | 3.28 | 2.95 | 2.85 |
| Days Sales in Inventory Ratio | 113.71 | 100.27 | 88.81 | 97.86 | 95.55 |
| Receivable Days | 94.32 | 96.05 | 111.28 | 123.73 | 128.07 |
| Capital Turnover Ratio | 1.07 | 1.21 | 1.21 | 1.18 | 1.25 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are generally strong. A good interest coverage ratio indicates the ability to meet interest obligations, while the equity dividend coverage ratio shows adequate coverage of dividend payments. Maintaining these ratios is crucial for financial stability. The healthcare industry relies on solid coverage ratios for consistent financial performance.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 17.4 | 7 | 8.56 | 6.78 | 4.4 |
| Equity Dividend Coverage Ratio | 4.17 | 1.89 | 3.57 | 2.63 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency. Low debt ratios and high equity ratios indicate a solid financial structure with minimal reliance on debt. This provides a stable base for future growth and financial flexibility. The healthcare industry benefits from strong solvency due to long-term investments and operational stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| Debt to Equity Ratio | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| Equity Ratio | 0.96 | 0.96 | 0.97 | 0.97 | 0.97 |
| Debt To Asset Ratio | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows a mixed performance. While the quick ratio indicates an ability to meet short-term obligations, the low cash ratio and operating cash flow ratio are areas of concern. A higher current ratio provides some buffer, but overall liquidity management could be improved. The healthcare industry often requires maintaining adequate liquidity to handle unforeseen expenses and operational needs.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.56 | 2.16 | 1.97 | 1.69 | 1.48 |
| Quick Ratio | 1.66 | 1.48 | 1.39 | 1.14 | 1.02 |
| Cash Ratio | 0.34 | 0.07 | 0.06 | 0.08 | 0.02 |
| Operating Cash Flow Ratio | -0.2 | 0.18 | 0.18 | 0.14 | 0.18 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.87 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 39.09 | Overvalued | 73.00 | 67.39 | 48.00 |
| 4 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 5 | Kilitch Drugs (India) Ltd | 6.61 | 21.17 | Neutral | 37.00 | 9.27 | 30.00 |
| 6 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Sakar Healthcare Ltd | 5.81 | 58.09 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 31.76 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -31.34 | Neutral | -4.82 | -3.00 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 26.36 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 35.36 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Lyka Labs Ltd | 4.77 | -24.93 | Neutral | -4.00 | -9.05 | -10.00 |
| 18 | Wanbury Ltd | 4.65 | 28.05 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management of Kopran Ltd. demonstrates a mixed performance. A positive aspect is the consistent promoter holding, indicating a strong alignment with shareholder interests. The company has also achieved sales growth over the past decade. However, there are concerns about the declining profit growth and fluctuating operating profit margins. The increasing debt levels also raise concerns about financial prudence.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 44.42% | Indicates confidence and alignment with shareholders |
| Sales Growth (10Y) | 7% | Shows consistent revenue expansion | |
| CONS | Compounded Profit Growth (3Y) | -14% | Indicates declining profitability |
| Debt/Equity Ratio (Increasing Trend) | Increasing | Suggests increased financial risk |
Financial Performance & Growth
Kopran Ltd. exhibits mixed financial growth. While sales have generally increased, profit growth has been inconsistent, especially in recent years. Additionally, the operating profit margin (OPM) has fluctuated, suggesting potential instability in operational efficiency.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | N/A | N/A | N/A | N/A | N/A | 2% |
| Compounded Profit Growth | N/A | N/A | N/A | N/A | N/A | -24% |
| OPM (%) | 11.33% | 11.67% | 17.67% | 9% | 12% | 12% |
The compounded profit growth has declined, with the TTM showing a negative value. The inconsistency in OPM suggests variability in operational efficiency.
Capital Efficiency & Returns
Kopran Ltd.'s capital efficiency and returns present a mixed outlook. While the Return on Capital Employed (ROCE) has seen fluctuations, the Return on Equity (ROE) has remained relatively stable but is not exceptionally high. The cash conversion cycle has lengthened, indicating potential inefficiencies in working capital management.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 14% | 15.67% | 23.67% | 8% | 14% | 10% |
| ROE (%) | N/A | N/A | N/A | N/A | N/A | 8% |
| Cash Conversion Cycle (Days) | 91.67 | 112 | 158 | 152 | 149 | 170 |
The ROCE has decreased in 2023 and 2025 compared to the period of 2020-2022. The increasing cash conversion cycle indicates that the company is taking longer to convert its investments in inventory and receivables into cash, which could strain liquidity.
Financial Health & Prudence
Kopran Ltd.'s financial health shows signs of potential weakness due to increasing debt levels. While the Interest Coverage Ratio is not explicitly provided, the rising borrowings suggest increased financial risk. Though the company consistently shares profits through dividends, the increasing reliance on debt is a concern.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 97.67 | 93.67 | 72 | 75 | 99 | 148 |
| Debt/Equity Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout (%) | 0% | 0% | 31.67% | 53% | 28% | 38% |
The Borrowings have increased significantly in the most recent year. This increased debt burden could potentially impact the company's ability to meet its financial obligations and may increase its vulnerability to economic downturns.
Strategic & Operational Indicators
The operational efficiency of Kopran Ltd. reveals areas of concern. Debtor Days and Inventory Days have generally increased over the years, indicating a slowdown in the collection of receivables and the turnover of inventory. Consequently, the Working Capital Days have also risen, suggesting that more cash is tied up in operational activities.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 76.33 | 83 | 91.67 | 108 | 126 | 125 |
| Inventory Days | 97 | 129.67 | 158.33 | 133 | 126 | 153 |
| Working Capital Days | 91.67 | 112 | 158 | 177 | 180 | 189 |
The increasing Debtor Days and Inventory Days suggest that the company's working capital management may be becoming less efficient. This trend could lead to cash flow problems and reduced operational flexibility.
Kopran Ltd. presents a moderate risk profile due to volatility in segment performance and increasing regulatory compliance cost trends. Though the company has a stable promoter holding, the increasing Debt levels indicate a potential financial risk.
Segment performance volatility
Kopran Ltd. indicates variability in segmental financial results, which has been derived from the quarterly results. The YOY Sales Growth % and YOY Profit Growth % demonstrate fluctuations. These fluctuations indicate potential operational risk.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth (%) | 2.11 | 66.76 | -8.31 | 19.88 | 4.24 | -6.86 | 30.45 | 0.58 | 24.99 | 19.18 | -0.68 | 4.61 | -7.37 |
| YOY Profit Growth (%) | 16.42 | 19.50 | -72.79 | -65.37 | -54.08 | -63.55 | 196.13 | 127.19 | 131.59 | 300.72 | -46.41 | -34.14 | -48.01 |
The segment performance volatility highlights the need for proactive risk management to ensure consistent overall financial health.
Regulatory compliance cost trends
The regulatory compliance cost trends for Kopran Ltd. can be inferred from the 'Expenses' data in the quarterly results. The expenses are increasing over the period. This increasing trend suggests a heightened regulatory burden, potentially affecting profitability.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses (₹ Cr) | 116.83 | 112.46 | 106.83 | 145.68 | 136.72 | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 |
The rising expenses due to regulatory compliance may necessitate strategic cost management to mitigate the financial impact.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe